Table 3.
Analysis of Circulating IgG Levels for 3 Target Peptide Antigens in HCC Patients at Different Stages
| Stage | Patients (n) | Control (n) | Z | P |
|---|---|---|---|---|
| p16a | ||||
| Group 1 | 1.66±0.58 (25) | 1.59±0.64 (132) | 0.97 | 0.331 |
| Group 2 | 1.86±0.79 (43) | 1.59±0.64 (132) | 2.51 | 0.012 |
| Group 3 | 2.08±1.03 (51) | 1.59±0.64 (132) | 3.36 | 0.0008 |
| CD25a | ||||
| Group 1 | 1.00±0.13 (25) | 0.95±0.13 (132) | −2.317 | 0.020 |
| Group 2 | 1.05±0.12 (43) | 0.95±0.13 (132) | −4.603 | <0.001 |
| Group 3 | 1.04±0.15 (51) | 0.95±0.13 (132) | −3.228 | <0.001 |
| FOXP3 | ||||
| Group 1 | 1.05±0.20 (25) | 0.97±0.21 (132) | −2.044 | 0.044 |
| Group 2 | 1.06±0.16 (43) | 0.97±0.21 (132) | −2.797 | 0.005 |
| Group 3 | 1.11±0.26 (51) | 0.97±0.21 (132) | −3.038 | 0.002 |
Notes: The antibody levels are expressed as mean ± SD in SBR. Group 1= BCLC stage 0+A, Group 2 = BCLC stage B, Group 3 = BCLC stage C+D.